10.10.2019 - 01:02 Uhr

Mundipharma: Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana® in fast-track procedure

Mundipharma welcomes the news that Swissmedic (the Swiss Agency for Therapeutic Products; the surveillance authority for medicines and medical devices in Switzerland) is conducting a fast-track review of Mundipharma Switzerland’s application to extend marketing authorisation for the SGLT2 inhibitor canagliflozin as an adjunct to the standard of care in adults with type 2 diabetes mellitus (T2DM) and stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria. The submission is based on data from the Phase III CREDENCE study, which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to the current standard of care.1

Last accessed September 2019.

Job code: MBL/DIAB-19029
Date of preparation: October 2019